Analyst Research

Report Title Price
Provider: Wright Reports
Provider: Thomson Reuters Stock Report
Provider: Stock Traders Daily
Provider: New Constructs, LLC

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Spectrum Pharmaceuticals Inc Comments On FY 2013 Guidance

Thursday, 21 Feb 2013 07:00am EST 

Spectrum Pharmaceuticals Inc announced that it expects revenues and operating income to increase in 2013. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $297 million and EBIT of $90 million for fiscal 2013.